Evalueserve

DECEMBER 6, 2021

On the other hand, Biotech heavily underperformed post Q1’21 primarily due to the shifting of focus towards cyclicals and negative sentiments arising as of result of greater regulatory clampdown on transformative deals and drug pricing. Global Healthcare Capital Markets Activity. Healthcare Funding – Normalization of ‘Cash Runways’.

Capital 98

Capital Globalization Biotech Marketing 98

Alpha Sense BI

MAY 28, 2024

The venture capital landscape continues to test the discipline and diligence of investors and startups alike. Like many other asset classes, venture capital continues to be impacted by lingering macroeconomic factors affecting funding and liquidity prospects. Interest rates are high.

Capital 69

Capital Startups Biotech Due Diligence 69

Alpha Sense BI

APRIL 29, 2024

Heading into the second half of 2024, venture capital investors remain cautious as they acknowledge persistent challenging dynamics in the landscape. While dry powder reserves have reached record highs, investors are wary about deploying capital with certain recent macroeconomic factors still fresh in mind.

Capital 52

Capital Due Diligence Biotech Startups 52

Alpha Sense BI

FEBRUARY 8, 2023

Attracting industry leaders, emerging fast-growth companies, and technology creators from around the world, life science corporations share their latest advances, leading research, and best practices — as well as their intentions to scale their digital health solutions — to the masses in hopes of securing capital.

Biotech 96

Biotech Research Innovation Capital 96

Alpha Sense BI

JANUARY 25, 2023

Moderna and BioTech, the pharmaceuticals companies behind the Moderna vaccines for the COVID-19 virus, just announced a new treatment this past December that would greatly reduce the chances of death from melanoma — stirring up substantial interest in investors to funnel capital. a potential cure for skin cancer.

Biotech 96

Biotech Pharmaceutical Hospitals Market Intelligence 96

Alpha Sense BI

JANUARY 26, 2024

Attracting industry leaders, emerging fast-growth companies, and technology creators from around the world, life science corporations share their latest advances, leading research, and best practices—as well as their intentions to scale their digital health solutions—to the masses in hopes of securing capital.

Biotech 59

Biotech Research Loss Algorithm 59

Alpha Sense BI

APRIL 19, 2024

On the other hand, 2022 and 2023 brought mass layoffs , falling market capitalizations, and a weakening of global tech spending. 2023 was all about learning the use cases of genAI, as companies raced to introduce their own genAI offerings and capabilities into a fiercely competitive market (i.e. OpenAI’s ChatGPT ).

Technology 69

Technology Technology Retail Biotech 69